Werewolf Therapeutics HOWL
NASDAQ HOWL
$0.99 +0.02 (+1.95%)
At close: Nov 11, 2026 · 4:00 PM EST

Werewolf Therapeutics (HOWL) EBITDA Margin (2022 - 2026)

Updated

Werewolf Therapeutics' EBITDA Margin came in at 45.76% for Q2 2026.

Analysis

Werewolf Therapeutics (HOWL) EBITDA Margin (2022 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Werewolf Therapeutics reported EBITDA Margin of -131.45%, up 475048.55 percentage points year-over-year; for FY2024, it was -3777.89%, down 3583.65 percentage points from FY2023.

  • Going back by year, EBITDA Margin was -194.25% in FY2023 (+140.80 pp) and -335.05% in FY2022.
  • The Q2 2026 figure represents the highest quarterly EBITDA Margin in data going back to Q2 2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 Werewolf Therapeutics 47.14 Mn -144.12 Mn - 45.76%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 45.76%
Dec 31, 2024 -132,706.67%
Jun 30, 2024 -1,619.07%
Mar 31, 2024 -2,250.40%
Dec 31, 2023 -832.91%
Sep 30, 2023 -149.33%
Jun 30, 2023 -69.71%
Mar 31, 2023 -262.95%
Dec 31, 2022 -172.44%
Sep 30, 2022 -244.16%
Jun 30, 2022 -356.49%
API Access

Werewolf Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=HOWL&period=max&api_key=YOUR_API_KEY